504 results on '"Hofmann W. -K."'
Search Results
102. Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin
103. Molecular pathogenesis of myelodysplastic syndrome: V851
104. Mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloid leukemia show distinct cytogenetic and DNA-mutation data as compared with bone marrow leukemic blasts: V573
105. BAALC associated gene expression signature pinpoints to a role in T-ALL: V392
106. High density SNP array allelokaryotyping of human acute lymphoblastic leukemia (ALL) xenografts in immunodeficient mice reveals genomic changes upon in vivo induction of chemoresistance: V389
107. Prognostic significance of BAALC expression in adult B-precursor acute lymphoblastic leukemia: V343
108. AsperGenius® PCR combined with galactomannan determination and MucorGenius® PCR analysis used for detection of fungal DNA in clinical samples of immunocompromised patients
109. Gene expression profiling of normal hematopoietic progenitor cells under treatment with imatinib in vitro
110. Imatinib induces apoptosis in CLL lymphocytes with high expression of Par-4
111. Significant Down-Regulation of baalc During Lineage Specific Hematopoietic Differentiation: O281
112. Comprehensive Transcriptional Profiling of Differentiating Human Hematopoietic Stem Cells Reveals a Lineage-Specific Genetic Signature in Normal Hematopoiesis: O243
113. Allele specific expression of Insulin-like growth factor 2 in myelodysplastic syndrome and normal hematopoietic cells: Reversal of a principle: P1053
114. Delta-like 1 (DLK1): A new key gene for the pathophysiology of myelodysplastic syndromes: P665
115. Resistance to Imatinib (STI571) by overexpression of dominant-negative phosphotyrosine phosphatase-1B (PTP1B) in Bcr-Abl positive cells: P638
116. Establishment of an Imatinib-resistant acute lymphoblastic leukemia cell line SupB15 as in vitro model of Imatinibresistance in Ph+ALL: P625
117. An open, randomized phase III study to test the efficacy of G-CSF priming and the feasability of CD34+ cell transplantation in elderly patients (>60 years) with acute myeloid leukemia: P559
118. Hypermethylation of cell cycle control genes: Comparative analysis in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome: V414
119. Gene expression profiling of hematopoietic stem cells can predict disease risk in patients with myelodysplastic syndrome: 993
120. Gene expression profiling can predict resistance to STI571 in Ph+ acute lymphoblastic leukemia: 920
121. Global gene expression analysis by oligonucleotide microarrays can detect aberrant signaling pathways in CD34+ cells from patients with myelofibrosis with myeloid metaplasia: 105
122. Detection of the BCR-ABL mutation E255K prior to STI571 treatment in patients with Ph+ acute lymphoblastic leukemia: 52
123. New Aspects of the Treatment of Patients with Low-Risk Myelodysplastic Syndromes
124. Interlaboratory comparison of a KIT D816V detection assay in patients with systemic mastocytosis by chip-based digital PCR
125. Analysis of the diagnostic performance of the AsperGenius (R) system in clinical samples of immunocompromised patients and in BAL fluid spiked with serially diluted Aspergillus fumigatus conidia
126. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
127. Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial
128. S1611 MARS: MUTATION-ADJUSTED RISK SCORE FOR ADVANCED SYSTEMIC MASTOCYTOSIS
129. Reply to Aloyz et al
130. 7 Molecular changes as detected by high-throughput genomic techniques in MDS
131. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasm with eosinophilia
132. Detection of Aspergillus DNA and azole resistance mutations from BAL samples of immunocompromised patients and from serially diluted Aspergillus fumigatus conidia in BAL fluid sensitivity comparison of two molecular assays
133. L 8 - Myelodysplastische Syndrome (MDS)
134. L 6 - Störungen der Leukozyten mit besonderer Berücksichtigung der Agranulozytose
135. The EUROSKI biomarker study: Analyzing the mechanisms of treatment-free remission in chronic myeloid leukemia
136. Diagnostic Performance of Contrast Enhanced Pulmonary Computed Tomography Angiography for the Detection of Angioinvasive Pulmonary Aspergillosis in Immunocompromised Patients
137. Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients
138. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy
139. CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME ON IMATINIB IN PATIENTS WITH MYELOID/LYMPHOID NEOPLASMS AND ASSOCIATED PDGFRB FUSION GENES IN CHRONIC OR BLAST PHASE
140. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-beta-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study
141. Identification of invasive fungal infections in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA microarray
142. Performance of combinations of Aspergillus PCR, multifungal DNA microarray, galactomannan, 1,3-beta-D-glucan and Aspergillus azole resistance PCRs in blood and BAL samples for diagnosis and characterization of invasive fungal infections in haematological patients
143. Low prevalence of cyp51A key mutations in Aspergillus fumigatus in Germany in primary clinical samples (blood, BAL, biopsies, CSF) and isolates of immunocompromised patients
144. Identification of invasive fungal diseases in immunocompromised patients by combining anAspergillusspecific PCR with a multifungal DNA-microarray from primary clinical samples
145. Allogeneic hematopoietic cell transplantation without fluconazole and fluoroquinolone prophylaxis
146. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis
147. Dosage effect of zero to three functional LBR-genes in vivo and in vitro
148. Azole-Resistance in Aspergillus fumigatus - Epidemiology and Detection in immunodeficient Patients in Germany
149. Detection of fungal DNA in Aspergillus PCR-negative tissue biopsy samples from immunocompromised hematological patients using DNA microarray technology improves diagnosis of invasive fungal infections (IFI)
150. Aspergillus specific PCR of specimens more adequately representing the infectious localization such as bronchoalveolar lavage, cerebrospinal fluid or tissue/effusion samples are superior to testing concurrent blood samples in immunocompromised patients with suspected invasive aspergillosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.